Accelerate Adaptive Trials with the IQVIA Biotech Master Protocol Unit

Biotech sponsors are increasingly turning to master protocols and adaptive clinical trials to accelerate development, reduce costs and generate stronger evidence. The IQVIA Biotech Master Protocol Unit (MPU) is purpose-built to help sponsors operationalize complex platform studies with speed, flexibility and precision, turning master protocols into a long-term strategic advantage.

Download the fact sheet to learn more:

• End-to-end master protocol expertise across planning, activation, execution and closeout
• Faster arm activation with shared infrastructure and continuous arm availability
• Predictable costs and transparency through arm-based budgeting and reconciliation
• Scalable, adaptive data infrastructure enabling real-time insights and rolling analyses
• Proven global experience across oncology, rare disease and emerging indications

Discover how IQVIA Biotech helps sponsors master adaptive trial complexity and bring therapies to patients faster.